.

Make Better Decisions

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Chinese Patent Office
Deloitte
Citi
Accenture
Fish and Richardson
Medtronic
Daiichi Sankyo
AstraZeneca
Dow
Farmers Insurance

Generated: November 18, 2017

DrugPatentWatch Database Preview

Teva Pharm Company Profile

« Back to Dashboard

What is the competitive landscape for TEVA PHARM, and when can generic versions of TEVA PHARM drugs launch?

TEVA PHARM has two hundred and sixty-eight approved drugs.

There are thirty-one US patents protecting TEVA PHARM drugs and there have been two Paragraph IV challenges on TEVA PHARM drugs in the past three years. There are thirty-four tentative approvals on TEVA PHARM drugs.

There are four hundred and fifteen patent family members on TEVA PHARM drugs in thirty-eight countries and three hundred and eighty-nine supplementary protection certificates in thirteen countries.

Summary for Teva Pharm

International Patents:415
US Patents:31
Tradenames:223
Ingredients:216
NDAs:268
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Teva Pharms Usa
CLOBETASOL PROPIONATE
clobetasol propionate
CREAM;TOPICAL074087-001Feb 16, 1994DISCNNoNo► Subscribe► Subscribe► Subscribe
Teva Pharms
RAMIPRIL
ramipril
CAPSULE;ORAL077470-001Jun 18, 2008ABRXNoNo► Subscribe► Subscribe► Subscribe
Teva Pharms Usa
AMOXICILLIN AND CLAVULANATE POTASSIUM
amoxicillin; clavulanate potassium
TABLET;ORAL065096-001Oct 29, 2002ABRXNoNo► Subscribe► Subscribe► Subscribe
Teva Pharms Usa
EPTIFIBATIDE
eptifibatide
INJECTABLE;INJECTION090854-001Jun 12, 2015APRXNoNo► Subscribe► Subscribe► Subscribe
Teva Pharms Usa
AMLODIPINE BESYLATE AND VALSARTAN
amlodipine besylate; valsartan
TABLET;ORAL091235-004Mar 30, 2015ABRXNoNo► Subscribe► Subscribe► Subscribe
Teva Pharms
OLANZAPINE
olanzapine
TABLET;ORAL076000-005Oct 24, 2011ABRXNoNo► Subscribe► Subscribe► Subscribe
Teva Pharms Usa
OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE
amlodipine besylate; hydrochlorothiazide; olmesartan medoxomil
TABLET;ORAL202491-002Nov 3, 2016ABRXNoNo► Subscribe► Subscribe► Subscribe
Teva Pharms
DOXEPIN HYDROCHLORIDE
doxepin hydrochloride
CONCENTRATE;ORAL071609-001Nov 9, 1987AARXNoYes► Subscribe► Subscribe► Subscribe
Teva Pharm
ARMONAIR RESPICLICK
fluticasone propionate
POWDER;INHALATION208798-002Jan 27, 2017RXYesNo► Subscribe► SubscribeY ► Subscribe
Teva Pharm
AIRDUO RESPICLICK
fluticasone propionate; salmeterol xinafoate
POWDER;INHALATION208799-002Jan 27, 2017RXYesNo► Subscribe► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Teva Pharm

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Teva Pharms Usa
COPAXONE
glatiramer acetate
FOR SOLUTION;SUBCUTANEOUS020622-001Dec 20, 1996► Subscribe► Subscribe
Teva Pharms Usa
COPAXONE
glatiramer acetate
INJECTABLE;SUBCUTANEOUS020622-003Jan 28, 2014► Subscribe► Subscribe
Teva Pharms Usa
COPAXONE
glatiramer acetate
FOR SOLUTION;SUBCUTANEOUS020622-001Dec 20, 1996► Subscribe► Subscribe
Teva Pharms Usa
COPAXONE
glatiramer acetate
FOR SOLUTION;SUBCUTANEOUS020622-001Dec 20, 1996► Subscribe► Subscribe
Teva Pharms Usa
COPAXONE
glatiramer acetate
INJECTABLE;SUBCUTANEOUS020622-003Jan 28, 2014► Subscribe► Subscribe
Teva Pharms Usa
COPAXONE
glatiramer acetate
INJECTABLE;SUBCUTANEOUS020622-002Feb 12, 2002► Subscribe► Subscribe
Teva Pharms Usa
COPAXONE
glatiramer acetate
INJECTABLE;SUBCUTANEOUS020622-002Feb 12, 2002► Subscribe► Subscribe
Teva Pharms Usa
COPAXONE
glatiramer acetate
INJECTABLE;SUBCUTANEOUS020622-003Jan 28, 2014► Subscribe► Subscribe
Teva Pharms Usa
COPAXONE
glatiramer acetate
INJECTABLE;SUBCUTANEOUS020622-003Jan 28, 2014► Subscribe► Subscribe
Teva Pharms Usa
COPAXONE
glatiramer acetate
INJECTABLE;SUBCUTANEOUS020622-002Feb 12, 2002► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for TEVA PHARM drugs

Drugname Dosage Strength Tradename Submissiondate
omacetaxine mepesuccinate
for Injection3.5 mg/vial
SYNRIBO
10/26/2016
omeprazole
Delayed-release Tablets20 mg
OMEPRAZOLE
6/3/2015
glatiramer acetate
Injection40 mg/mL, 1 mL pre-filled syringe
COPAXONE
2/26/2014
glatiramer acetate
Injection40 mg/mL, 1 mL pre-filled syringe
COPAXONE
1/29/2014
cyclobenzaprine hydrochloride
Extended-release Capsule15 mg and 30 mg
AMRIX
8/11/2008

Premature patent expirations for TEVA PHARM

Expiration due to failure to pay maintenance fee

Patent Number Expiration Date
► Subscribe ► Subscribe

Non-Orange Book Patents for Teva Pharm

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,169,774Cephalotaxane derivatives and their processes of preparation and purification► Subscribe
6,655,381 Pre-metered dose magazine for breath-actuated dry powder inhaler► Subscribe
9,526,851Dose counters for inhalers, inhalers and methods of assembly thereof► Subscribe
9,108,010Dose counters for inhalers, inhalers and methods of assembly thereof► Subscribe
6,613,900 Cephalotaxane derivatives and process for their preparation► Subscribe
6,831,180 Cephalotaxane derivatives and process for their preparation► Subscribe
9,533,111Dose counters for inhalers, inhalers and methods of assembly thereof► Subscribe
9,463,289Dose counters for inhalers, inhalers and methods of assembly thereof► Subscribe
9,526,850Dose counters for inhalers, inhalers and methods of assembly thereof► Subscribe
9,345,664Process for preparing a medicament► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Teva Pharm Drugs

Country Document Number Estimated Expiration
European Patent Office2987522► Subscribe
Canada2441428► Subscribe
South Korea20130103826► Subscribe
European Patent Office2514462► Subscribe
Portugal2177223► Subscribe
South Korea100663113► Subscribe
Uruguay26793► Subscribe
Austria281861► Subscribe
Spain2520966► Subscribe
South Korea20160038057► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Teva Pharm Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB99/046United Kingdom► SubscribePRODUCT NAME: EPTIFIBATIDE OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTERED: CH 54054 19970227; CH 54050 19970227; UK EU/1/99/109/001 19990701; UK EU/1/99/109/002 19990701
C/GB98/043United Kingdom► SubscribePRODUCT NAME: DIPYRIDAMOLE, OPTIONALLY IN THE FORM OF A PHYSIOLOGICALLY ACCEPTABLE SALT, AND O-ACETYLSALICYLIC ACID, OPTIONALLY IN THE FORM OF A PHYSIOLOGICALLY SALT, I.E. ASASANTIN RETARD; REGISTERED: FR NL 22160 19970709; UK 00015/0224 19980512
00677Netherlands► SubscribePRODUCT NAME: COMBINATIE VAN DAPAGLIFLOZINE OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN EN METFORMINE OF EEN FARMACEITISCH AANVAARDBAAR ZOUT DAARVAN, ZOALS BESCHERMD DOOR HET BASISOCTROOI EP 1506211B1; REGISTRATION NO/DATE: EU/1/13/900 20140121
2 5010-2012Slovakia► SubscribePRODUCT NAME: RILPIVIRINHYDROCHLORID/TENOFOVIRDIZOPROXILFUMARAT; REGISTRATION NO/DATE: EU/1/11/737/001 - EU/1/11/737/002 20111128
2011005Lithuania► SubscribePRODUCT NAME: NAPROXENUM + ESOMEPRAZOLUM; REGISTRATION NO/DATE: LT/1/10/2302/001-LT/1/10/2302/012 20110126
854Luxembourg► SubscribePRODUCT NAME: COMBINAISON DE RILPIVIRINE OU UNE FORME THERAPEUTIQUE EQUIVALENTE QUI EN DERIVE TELLE QUE PROTEGEE PAR LE BREVET DE BASE, TEL QU'UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE RILPIVIRINE, INCLUANT LE SEL CHLORHYDRATE DE RILPIVIRINE, ET TENOFOVIR, EN PARTICULIER LE FUMARATE DE TENOFOVIR DISOPROXIL
2016039Lithuania► SubscribePRODUCT NAME: ATAZANAVIRAS + KOBICISTATAS; REGISTRATION NO/DATE: EU/1/15/1025 20150713
2009004Lithuania► SubscribePRODUCT NAME: ESTRADIOLI VALERAS + DIENOGESTUM; NAT. REGISTRATION NO/DATE: LT/1/09/1512/001, 2009 04 06 LT/1/09/1512/002, 2009 04 06 LT/1/09/1512/003 20090406; FIRST REGISTRATION: BE 327792 20081103
80001Netherlands► SubscribePRODUCT NAME: ZOLMITRIPTANUM, DESGEWENST IN DE VORM VAN EEN FYSIOLOGISCH AANVAARDBAAR ZOUT OF VAN EEN SOLVAAT; NAT. REGISTRATION NO/DATE: RVG 21079, RVG 21080 19970925; FIRST REGISTRATION: GB PL 12619/0116 19970307
90021Netherlands► SubscribePRODUCT NAME: ZALEPLONUM; REGISTRATION NO/DATE: EU/1/99/099/001 - EU/1/99/099/006, EU/1/99/102/001 - EU/1/99/102/006 19990312
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Daiichi Sankyo
Novartis
Medtronic
Argus Health
Merck
Covington
Cerilliant
AstraZeneca
US Department of Justice
Fuji

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot